Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Geron logo

MarketBeat

Sun, September 13, 2026 at 5:01 PM GMT+3 5 min read

GERN +1.48%

Key Points

Interested in Geron Corporation? Here are five stocks we like better.
Geron expects RYTELO's 2026 revenue near the high end of its $230 million–$240 million guidance, supported by three consecutive quarters of growth, a 24% first-half revenue increase, and lower operating expenses.
The company is expanding RYTELO use in community treatment settings and prioritizing second-line, earlier treatment of lower-risk MDS, where about 80% of patients are treated in the community.
Geron is reviewing partnership and commercial options for Europe, while preserving capital flexibility; it reported more than $320 million in cash and continues regulatory discussions on its myelofibrosis study.

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.

During the Cantor Healthcare Conference, Chief Executive Officer Harout Semerjian said Geron generated $57.5 million in net revenue during the second quarter, nearly $5 million above the preceding quarter. He said the company has now recorded three consecutive quarters of growth and reported that RYTELO revenue rose 24% in the first half of the year while operating expenses declined 4%.

→ MarketBeat Week in Review – 09/07 - 09/11

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

"We definitely see a path to profitability," Semerjian said, noting that Geron's revenue outlook and operating-expense guidance are both in the $230 million to $240 million range. However, he said the company is also focused on building a broader business and maintaining financial flexibility for future opportunities.

Community Expansion and Earlier-Line Use

Semerjian said Geron's commercial strategy has progressed from early engagement with academic medical centers toward greater penetration of community treatment settings. He said roughly 80% of lower-risk MDS patients are seen and treated in the community, particularly those in the second-line population targeted by RYTELO.

→ Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?

Geron is focusing on high-volume community accounts and on increasing use within accounts that have already adopted the treatment. Semerjian characterized this as a shift toward "depth" of use while the company continues to add new accounts.

The company is also seeking to move utilization toward earlier treatment lines. Semerjian said more than one-third of patients receiving RYTELO are now coming from earlier lines of therapy. He said Geron's label and recently updated NCCN guidelines support use in the second-line setting, where the company believes its data are strongest and treatment duration may be longer than in later-line use.

→ Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers

While physicians may continue to use the therapy organically in later-line patients, Semerjian said Geron's commercial efforts will center on second-line treatment.

European Strategy Under Review

Geron has global rights to RYTELO and has received European Medicines Agency approval. Semerjian said the company plans to update investors by the end of the year on its strategy for markets outside the United States, including Europe.

Potential approaches could include partnerships, targeted commercial activity or use of contract sales organizations, he said. Geron does not plan to pursue a traditional model of building large country-by-country commercial teams in Europe.

Semerjian said the company is weighing pricing and policy considerations, including the evolving most-favored-nation, or MFN, discussion. He said management intends to preserve its flexibility and avoid making decisions that could undermine the company financially while pursuing broader patient access.

"RYTELO needs to be everywhere in the world, helping patients around the world," Semerjian said. "We don't necessarily need to be everywhere in the world."

Myelofibrosis Study Discussions Continue

Chief Medical Officer Joe Eid provided an update on Geron's relapsed/refractory myelofibrosis study in patients who have failed JAK inhibitors. The trial, which completed enrollment in September of last year, uses overall survival as its primary endpoint.

Eid said Geron has been discussing the interim analysis with U.S. and European regulators to ensure the study's framework reflects current regulatory expectations. The company is evaluating whether an interim result could potentially support a supplemental new drug application, though its previously communicated base case remains a final analysis in the second half of 2028.

The study could continue unchanged, reach a futility outcome or produce a positive result, Eid said. He added that Geron intends to complete regulatory discussions before any unblinding trigger is reached in order to preserve trial integrity.

The study permits certain control-arm patients to cross over to active treatment after a washout period and company review. Eid said the trial was designed with a buffer intended to prevent crossover from diluting the study's statistical power.

Business Development and Capital Position

Semerjian said Geron had more than $320 million in cash and has not exercised the final two tranches of a $125 million Pharmakon debt facility. The company recently added a chief business officer and is building capabilities to evaluate potential partnerships and business-development opportunities.

While RYTELO growth remains Geron's top priority, Semerjian said the company may consider assets that fit its existing commercial and medical infrastructure. He said Geron does not need multibillion-dollar peak-sales assets to support its strategy and believes its available capital provides flexibility if attractive opportunities emerge.

About Geron (NASDAQ:GERN)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing treatments for myeloid hematologic malignancies, including certain bone marrow cancers. The company's approach centers on imetelstat, a telomerase inhibitor designed to target malignant stem and progenitor cells.

Geron's lead product, Rytelo (imetelstat), is approved in the United States for adults with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia requiring or having failed treatment with erythropoiesis-stimulating agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

The article "Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands" was originally published by MarketBeat.

View MarketBeat's top stocks for September 2026.